BCAB
BCAB
NASDAQ · Biotechnology

Bioatla Inc

$4.84
+0.49 (+11.26%)
As of May 16, 2:28 AM ET ·
Financial Highlights (FY 2026)
Revenue
2.55M
Net Income
-75,914,697
Gross Margin
Profit Margin
-2,980.4%
Rev Growth
+100.0%
D/E Ratio
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 33.3% 33.3% 33.3%
Operating Margin -2,985.5% -36.5% -29.8% -32.7%
Profit Margin -2,980.4% -28.2% -25.1% -26.2%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 2.55M 2.16M 1.98M 2.25M
Gross Profit 720.3K 659.4K 748.0K
Operating Income -76,048,437 -790,128 -590,564 -735,733
Net Income -75,914,697 -609,365 -497,914 -589,745
Gross Margin 33.3% 33.3% 33.3%
Operating Margin -2,985.5% -36.5% -29.8% -32.7%
Profit Margin -2,980.4% -28.2% -25.1% -26.2%
Rev Growth +100.0% +2.0% +14.6% +17.3%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 6.12M 5.92M 6.90M
Total Equity 9.93M 9.80M 9.64M
D/E Ratio 0.62 0.60 0.72
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -76,888,990 -937,252 -843,277 -1,004,481
Free Cash Flow -606,690 -515,846 -697,858